Serum cytokeratin 19 fragments: A dedifferentiation marker in advanced thyroid cancer

European Journal of Endocrinology

Volumn 167, Issue 6, 2012, Pages 793-797

  Giovanella, Luca ^a,b,c   Treglia, Giorgio ^d   Verburg, Frederik A ^e,f   Salvatori, Massimo ^d   Ceriani, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c Laboratory of Endocrinology and Tumor Markers   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 19 FRAGMENT; IODINE 131; THYROGLOBULIN;

ADULT; ARTICLE; CANCER RESISTANCE; CARCINOMA CELL; DIFFERENTIATED THYROID CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THYROGLOBULIN BLOOD LEVEL; THYROIDECTOMY;

ADULT; AGED; FEMALE; HUMANS; KERATIN-19; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84869069654     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0660     Document Type: Article

References (28)

1. Sobin LH, Gospodarowicz M, Wibtekind C (Eds). International Union againt Cancer. TNM classification of malignant tumours. 2009. 7th Edition. Wiley Blackwell: Oxford.
2. DeGroot LJ, Kaplan EL, McCormick M& Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 1990 71 414-424. (doi:10.1210/jcem-71-2-414)
3. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA & Smit JW. Survival and death causes in differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2006 91 313-319. (doi:10.1210/jc.2005- 1322)
4. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism 2006 91 2892-2899. (doi:10.1210/jc.2005-2838)
5. Haugen BR & Kane MA. Approach to the thyroid cancer patient with extracervical metastases. Journal of Clinical Endocrinology and Metabolism 2010 95 987-993. (doi:10.1210/jc.2009-2305)
6. Sherman SI. Cytotoxic chemotherapy for differentiated thyroid carcinoma. Clinical Oncology 2010 22 464-468. (doi:10.1016/j. clon.2010.03.014)
7. Dancey J & Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nature Reviews. Drug Discovery 2003 2 296-313. (doi:10.1038/nrd1066)
8. Gild ML, Bullock M, Robinson BG & Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nature Reviews. Endocrinology 2011 7 617-624. (doi:10.1038/nrendo.2011.141)
9. Schlumberger M & Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. European Journal of Endocrinology 2012 166 5-11. (doi:10.1530/EJE-11-0631)
10. Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European Journal of Endocrinology 2009 161 923-931. (doi:10.1530/EJE-09-0702)
11. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ et al. Phase II trial of sorafenib in advanced thyroid cancer. Journal of Clinical Oncology 2008 26 4714-4719. (doi:10.1200/JCO.2008.16.3279)
12. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M et al. Phase II trial of sorafenib in metastatic thyroid cancer. Journal of Clinical Oncology 2009 27 1675-1684. (doi:10.1200/JCO.2008.18.2717)
13. Schroder S, Wodzynski A & Padberg B. Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies. Der Pathologe 1996 17 425-432. (doi:10.1007/s002920050181)
14. Raphael SJ, McKeown-Eyssen G & Asa SL. High-molecular-weight cytokeratin 19 in the diagnosis of thyroid tumours. Modern Pathology 1994 7 295-300.
15. Sarwar M, Tomiyoshi K, Inoue T, Fukazawa K & Endo K. CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay. Annals of Nuclear Medicine 1994 8 301-306. (doi:10.1007/BF03165035)
16. Giovanella L, Ceriani L, Ghelfo A & Maffioli M. Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. International Journal of Biological Markers 2008 23 54-57.
17. Gao Y, Lu H, Yuan Z & Zhu R. Tumormarkers in thyroid carcinoma with pulmonarymetastases after thyroidectomy. Laboratory Medicine 2009 40 30-34. (doi:10.1309/LM8FZXW08BRJSJSR)
18. Giovanella L, Suriano S, Ceriani L & Verburg FA. Undetectable thyroglobulin in patients with differentiated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clinical Nuclear Medicine 2011 36 109-112. (doi:10.1097/RLU.0b013e318203bb84)
19. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D & Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. European Journal of Endocrinology 1999 141 443-457. (doi:10.1530/eje.0.1410443)
20. Antonelli A, Fallahi P, Ferrari SM, Carpi A, Berti P, Materazzi G, Minuto M, Guastalli M& Miccoli P. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomedicine and Pharmacotherapy 2008 62 559-563. (doi:10.1016/j. biopha.2008.07.056)
21. Isic T, Savin S, Cvejic D, Marecko I, Tatic S, Havelka M &Paunovic I. Serum Cyfra 21.1 and galectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors. Journal of Cancer Research and Clinical Oncology 2010 136 1805-1812. (doi:10. 1007/s00432-010-0838-3)
22. Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T et al. The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines. International Journal of Cancer 2001 91 468-473. (doi:10.1002/1097-0215(200002)9999:9999〈:: AIDIJC1082〉3.0.CO;2-T)
23. Kim HS, Chang I, Kim JY, Choi KM & Lee MS. Caspase-mediated p65 cleavage promotes TRAIL-induced apoptosis. Cancer Research 2005 65 6111-6119. (doi:10.1158/0008-5472.CAN-05-0472)
24. Wu F, Fujita J, Murota M, Li JQ, Ishida T, Nishioka M, Imaida Y &Kuriyama S. CYFRA 21-1 is released in TNF-alpha-induced apoptosis in the hepatocellular carcinoma cell line HuH-7. International Journal of Oncology 2002 21 441-445.
25. Bass MB, Sherman SI, Schlumberger MJ, Davis MT, Kivman L, Khoo HM, Notari KH, Peach M, Hei YJ & Patterson SD. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2012 95 5018-5027. (doi:10.1210/jc.2010-0947)
26. Riesco-Eizaguirre G & Santisteban P. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. Endocrine-Related Cancer 2007 14 957-977. (doi:10.1677/ERC-07-0085)
27. Rivera M, Ghossein RA, Schoder H, Gomez D, Larson SM &Tuttle RM. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose positron emission tomography-positive thyroid carcinoma. Cancer 2008 113 48-56. (doi:10.1002/cncr.23515)
28. Crabbs SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L et al. Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. Journal of Clinical Oncology 2009 27 404-410. (doi:10.1200/JCO.2008.16. 2545)